Kiora Pharmaceuticals Inc
KPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001372514
No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.
Other share classesKPHMW
13F holders, Q4 2022
Institutional positions in Kiora Pharmaceuticals Inc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +2 vs. Q3 2022
- Shares held
- 151.2K
- +117.1K (+343.4%) vs. Q3 2022
- Total value
- $518.8K
- +$309.8K (+148.2%) vs. Q3 2022
- New holders
- 4
- 2 more added
- Sold out
- 2
- 1 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KPRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $2.91M |
| Q1 2026 | 18 | $654.7K |
| Q4 2025 | 19 | $1.39M |
| Q3 2025 | 17 | $1.71M |
| Q2 2025 | 16 | $2.68M |
| Q1 2025 | 18 | $3.87M |
| Q4 2024 | 16 | $4.16M |
| Q3 2024 | 19 | $5.38M |
| Q2 2024 | 17 | $5.97M |
| Q1 2024 | 24 | $7.87M |
| Q4 2023 | 15 | $159.5K |
| Q3 2023 | 14 | $91.9K |
| Q2 2023 | 18 | $425.2K |
| Q1 2023 | 14 | $283.6K |
| Q4 2022 | 11 | $518.8K |
| Q3 2022 | 9 | $209.0K |
| Q2 2022 | 14 | $391.0K |
| Q1 2022 | 16 | $517.0K |
| Q4 2021 | 13 | $1.22M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Kiora Pharmaceuticals Inc; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Walleye Capital LLC | 83,300 | $285.7K | 0.01% | +83,300 | New |
| Warberg Asset Management LLC | 33,000 | $113.2K | 0.03% | +33,000 | New |
| BlackRock Inc. | 14,462 | $49.6K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 11,679 | $40.1K | 0.00% | +11,679 | New |
| Tower Research Capital LLC (TRC) | 4,276 | $15.0K | 0.00% | +4,276 | New |
| UBS Group AG | 4,254 | $14.6K | 0.00% | +2,111+98.5% | Added |
| Morgan Stanley | 116 | $397 | 0.00% | −2,258−95.1% | Reduced |
| US Bancorp | 67 | $230 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 7 | $24 | 0.00% | +2+40.0% | Added |
| Albion Financial Group | 6 | $21 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 36 | $0 | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −14,008−100.0% | Sold out |
| Spartan Fund Management Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |